Description: Health Canada has approved CimziaTM, the only PEGylated anti-TNF (Tumour Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
Patients experienced a significant reduction in the signs and symptoms of RA at week 24 with some showing clinical responses within one to two weeks